Acipimox

HCID 5310993CAS 51037-30-0

기본 정보

표준 SMILES
Cc1cnc(C(=O)O)c[n+]1[O-]
InChIKey
DJQOOSBJCLSSEY-UHFFFAOYSA-N
분자식
C6H6N2O3
평균 분자량
154.12 g/mol
단동위원소 질량
154.03784205

개요

5-methyl-4-oxido-2-pyrazin-4-iumcarboxylic acid is a pyrazinecarboxylic acid.

이름 및 식별자

우선 이름
Acipimox
IUPAC
5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid
영어명
Acipimox
분자식
C6H6N2O3
분자량
154.12

이름 및 동의어

ACIPIMOX51037-30-0OlbetamOlbemox5-methylpyrazine-2-carboxylic acid 4-oxide5-Methylpyrazinecarboxylic acid 4-oxide5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acidDTXSID2046202NSC-759818K9AY9IR2SDDTXCID00262025-CARBOXY-2-METHYLPYRAZIN-1-IUM-1-OLATE
이름 더 보기
K-9321AcimusAcipimox (K-9321)Acyclovir therapyAcipiMox-13C2,15N2Acipimox USP/EP/BPAcipimox - Bio-X ?
AcipimoxumRefChem:552678C10AD06256-928-35-Carboxy-2-methylpyrazine 1-oxideMFCD008657572-CARBOXY-5-METHYLPYRAZINE 4-OXIDEACIPIMOX [WHO-DD]

데이터베이스 식별자

CAS
51037-30-0
PubChem CID
5310993
DTXSID
DTXSID2046202
ChEMBL
CHEMBL345714
ChEBI
CHEBI:94688
UNII
K9AY9IR2SD
EC Number
256-928-3
Nikkaji
J10.290C

물성

구조 계산 물성

XLogP
-1
극성 표면적
75.7 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
4
회전 가능 결합 수
1
무거운 원자 수
11

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Antilipidemics

Pharmaceuticals -> Listed in ZINC15

물리화학적 성질

녹는점
177 · 177-180 °C
끓는 점
539 · 539.0±45.0 °C(Predicted)
밀도
1.44 · 1.44±0.1 g/cm3(Predicted)
저장 조건
2 · Inert atmosphere,2-8°C
용해도
메탄올, 물(100mM), DMSO(100mM), 에탄올(25°C에서 <1mg/ml) 및 1M NH4OH(1mg/ml)에 용해됩니다.
물리적 상태
고체

화학적 성질

Yellow Solid

안전 및 규제

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 41.7% (30 of 72) of reports.

Warning

H319 (58.3%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

P264+P265, P280, P305+P351+P338, and P337+P317 (click each P-code to see the statement)

Aggregated GHS information provided per 72 reports by companies from 3 notifications to the ECHA C&L Inventory.

유해성 정보

Hazard Classes and CategoriesEye Irrit. 2A (58.3%)

안전 데이터

wgk
3
rtecs
UQ2453000
독성
LD50 orally in mice: 3500 mg/kg (Ambrogi)
HS 번호
2933.99.8290
risk_code
36
hazard_code
Xi

화학 및 산업

약리 정보

ATC Code · 3건

C10AD06

C - Cardiovascular system

QC - Cardiovascular system

Mechanism of ActionAcipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.
MeSH Pharmacological ClassificationSubstances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
응용 분야 · 2건

개요Acipimox is a nicotinic acid derivate that structurally related to nicotinic acid. Like nicotinic acid, lowers lipids effectively, but unlike nicotinic acid, acipimox is longer acting and therefore much less prone to produce free fatty acid rebounding. It is usually employed in man in the therapy of hypertriglyceridemia. In addition to its lipid lowering activity, it produces a beneficial elevation of the anti-atherogenic high density lipoprotein subfraction, HDL2. Acipimox is recommended as a lipid-lowering agent to treat hyperlipidemia in patients with noninsulin dependent diabetes mellitus.

용도Acipimox is a long-acting antilipemic agent and used for the treatment of hyperlipoproteinemias, in particular hypertriglyceridemias, and as adjunctive therapy for affecting cholesterol metabolism.

제조 방법 · 1건

Synthesis of acipimox: Under cooling and stirring, 78 g of maleic anhydride was dissolved in a solution of 60 ml of chloroform, and 40 ml of 30% hydrogen peroxide was added. After 2 h, 4.8 g of 5-Methyl-2-pyrazinecarboxylic acid was added, and the temperature was kept at 0-5 °C for 2 d. The maleic acid was filtered off. Concentrate to a small volume, add ethyl acetate, and filter to obtain 1.1 g of acipimox, the melting point of which is 178-180 °C.

공급사50 곳

北京华美互利生物化工010-56205725 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
温州共赢化学有限公司+86-0086-577-64498589 +86-15355981851 · [email protected]
爱斯特(成都)生物制药股份有限公司+86-28-85122536 85324413 · [email protected]

관련 반응

4건

연결된 노트

불러오는 중…